Ajinomoto Co., Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shigeo Nakamura
- Full Time Employees
- 34,862
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 15-1, Kyobashi 1-chome Tokyo Japan 104-8315
- IPO Date
- Feb 8, 2010
- Website
- ajinomoto.co.jp
- Similar Companies
- Business
- Ajinomoto Co., Inc. is a Japan-based multinational corporation primarily engaged in the food and healthcare industries. Founded in 1909 and headquartered in Chuo-ku, Tokyo, Ajinomoto operates globally, offering a diverse portfolio of products across three main business segments: Seasonings and Foods; Frozen Foods; and Healthcare and Other businesses. The Seasonings and Foods segment provides seasonings, processed foods, nutritional products, solutions, and ingredients including brands like AJIPHASE® and AJICAP®. The Frozen Foods segment offers a wide range of frozen meals and food products. The Healthcare and Other segment supplies pharmaceutical- and food-use amino acids, biopharmaceutical services, functional materials, and gene therapies. Recent major changes include Ajinomoto’s strategic acquisitions and partnerships aimed at expanding its presence in sustainable and next-generation protein solutions. In 2025, Ajinomoto entered a strategic partnership with v2food and acquired Daring Foods to accelerate the development and global scaling of plant-based protein products, leveraging v2food’s advanced protein technology and Daring’s existing US market footprint. Additionally, Ajinomoto sold its entire equity stake in Ajinomoto Althea, a US-based aseptic fill-finish contract development and manufacturing organization (CDMO), to focus more on high-value-added business models based on proprietary technologies. The company also acquired Forge Biologics for $620 million to strengthen its biopharmaceutical service capabilities, particularly in gene therapy. Furthermore, Ajinomoto Health & Nutrition North America launched new product platforms addressing sodium reduction, taste enhancement, and formulation efficiency in 2025. Ajinomoto operates extensively across Japan, Asia, the Americas, and Europe, targeting both consumer and industrial customers in the food, health, and biotech fields. The company continues to leverage its historical expertise in amino acid technology to innovate in nutrition, pharmaceuticals, and sustainable food systems globally and pursues growth through its global network and investments in next-generation food and healthcare technologies. Ajinomoto employs approximately 35,000 people worldwide and reported revenue exceeding 1.5 trillion yen in recent fiscal years. Its comprehensive offerings serve diverse markets from everyday consumer food products to specialized healthcare and biopharma solutions.
AI Needs Ajinomoto's Film, But Its CEO Won't Raise Prices Just Because
Ajinomoto Q4 Earnings: The Good And The Bad
Analyzing J. M. Smucker (NYSE:SJM) and Ajinomoto (OTCMKTS:AJINY)
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
Is MSG Maker Ajinomoto Sitting on an AI Goldmine? This Investor Thinks So
Critical Contrast: Ajinomoto (OTCMKTS:AJINY) vs. J. M. Smucker (NYSE:SJM)
Palliser Capital Publishes Value Enhancement Plan for Ajinomoto
Ajinomoto Co., Inc. (AJINY) Q3 2026 Earnings Call Transcript
Ajinomoto Co., Inc. (AJINY) Q2 2026 Earnings Call Transcript
Ajinomoto Co., Inc. - Special Call
Ajinomoto Co., Inc. (AJINY) Q1 2026 Earnings Call Transcript
Ajinomoto Co., Inc. (AJINY) Q4 2025 Earnings Call Transcript
L-Phenylalanine Market Insights and Forecast to 2030 Featuring Profiles (SWOT, Sales, Prices) of Key Players - Evonik, Ajinomoto, Daesang, and Wuxi Jinghai Amino Acid Co.
L-Alanyl-L-Glutamine Market Report 2025: Includes Insights Into the Sales, Revenue, Price, Gross Margin & SWOT of Kyowa Hakko, Ajinomoto, and Evonik
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
Ajinomoto Co., Inc. (AJINY) Q2 2024 Earnings Call Transcript
Ajinomoto Co., Inc. (AJINY) Q1 2024 Earnings Call Transcript
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Essential Japanese Semi Companies For The Reshoring Age
Ajinomoto: Food, Biotech, And Semis All-In-One